YD Bio Stock Price, News & Analysis

YD Bio Limited (YDESW) is a biopharmaceutical company that focuses on blood-based cancer detection and the development of stem cell- and exosome-based therapeutics. According to available information, the company aims to address diseases with high unmet medical need and also acts as a trusted supplier of clinical testing drugs for pharmaceutical companies.

The company’s work in blood-based cancer detection centers on identifying cancer through analysis of blood samples, which can support earlier diagnosis and monitoring. In addition, YD Bio Limited is involved in stem cell-based therapeutics and exosome-based therapeutics. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering potential treatments for injuries, degenerative diseases, and immune disorders. Exosome-based approaches focus on cell-derived vesicles that may be used as therapeutic agents or delivery vehicles in a range of disease areas.

YD Bio Limited also positions itself as a supplier of clinical testing drugs to pharmaceutical companies. In this role, it provides drugs used in clinical testing environments, supporting research and development activities in the broader pharmaceutical sector.

From a corporate and regulatory perspective, YD Bio Limited is a foreign private issuer that reports to the U.S. Securities and Exchange Commission on forms such as Form 20-F and Form 6-K. A Form 6-K filed on September 19, 2025, states that the company was incorporated on February 6, 2024 and that its principal executive office is located in Taipei City, Taiwan.

The same Form 6-K describes a change in the company’s independent registered public accounting firm. YD Bio Limited notified CBIZ CPAs P.C. that its engagement for audit and related services was terminated as of September 16, 2025. The decision was approved by the company’s audit committee and board of directors. The filing notes that, since the company’s inception and through the termination date, the reports of CBIZ CPAs on the company’s consolidated financial statements did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principle, other than an explanatory paragraph relating to substantial doubt about the company’s ability to continue as a going concern.

The Form 6-K further states that, during the period from inception through the termination date, there were no disagreements between YD Bio Limited and CBIZ CPAs on matters of accounting principles or practices, financial statement disclosure, or auditing scope or procedure that would have required reference in the audit reports. The company also reports that none of the events described in Item 16F(a)(1)(v)(A) through (D) of Form 20-F occurred in relation to CBIZ CPAs.

Effective as of September 17, 2025, YD Bio Limited engaged ARK Pro CPA & Co as its new independent registered public accounting firm for the fiscal year ending December 31, 2025. The decision to engage ARK Pro CPA & Co was approved by both the audit committee and the board of directors. The Form 6-K states that, from the company’s inception through the engagement date, YD Bio Limited had not consulted with ARK Pro CPA & Co on the application of accounting principles to any specified transaction or on the type of audit opinion that might be rendered, and had not received written or oral advice that was an important factor in decisions about accounting, auditing, or financial reporting issues.

The filing also notes that, over the same period, YD Bio Limited did not consult with CBIZ CPAs regarding the issues described in the paragraphs addressing consultations with ARK Pro CPA & Co. In connection with the change in certifying accountant, the company provided CBIZ CPAs with a copy of the disclosures made in the Form 6-K and requested a letter addressed to the SEC indicating whether CBIZ CPAs agreed with those statements. A copy of that letter is furnished as Exhibit 16.1 to the Form 6-K.

Overall, YD Bio Limited presents itself as a biopharmaceutical company working in cancer detection, stem cell therapy, and exosome-based therapeutics, while also supporting pharmaceutical companies through the supply of clinical testing drugs. Its SEC filings provide additional context on its corporate governance and auditor relationships as a foreign private issuer.